Greenwich LifeSciences Inc. has announced the ongoing global expansion of their Phase III FLAMINGO-01 trial, focusing on GLSI-100, a novel breast cancer vaccine immunotherapy. This trial is now active at over 120 sites across the United States and Europe. GLSI-100 combines the HER2-derived GP2 peptide with GM-CSF and aims to prevent breast cancer recurrences. In a prior Phase II trial, promising results were observed, showing no metastatic recurrences in immunized patients. The company has outlined a strategy to accelerate commercialization of GLSI-100, emphasizing advanced manufacturing readiness and strong academic partnerships. Results from the Phase III trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.